Do galectins play a role in venous thrombosis? a review

Thrombosis Research

Volumn 125, Issue 5, 2010, Pages 373-376

  Diaz, Jose A ^a   Ramacciotti, Eduardo ^a   Wakefield, Thomas W ^a  

^a Cardiovascular Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; BINDING PROTEIN; GALECTIN; GALECTIN 1; GALECTIN 3; GALECTIN 3 BINDING PROTEIN; PADGEM PROTEIN; PHOSPHATIDYLSERINE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

BINDING AFFINITY; CELL ACTIVATION; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROSIS; HUMAN; INFLAMMATION; PLATELET MICROPARTICLE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; THROMBOCYTE AGGREGATION; THROMBOGENESIS; VEIN THROMBOSIS;

ANIMALS; GALECTINS; HUMANS; MODELS, CARDIOVASCULAR; VEINS; VENOUS THROMBOSIS;

EID: 77951938293     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2009.11.011     Document Type: Review

References (52)

1. Heit J.A., C.A., and Anderson F.J. Estimated annual number of incident and recurrent, non-fatal venous thromboembolism (VTE) events in the US. Blood 106 (2005) 11
2. Wakefield T.W., Myers D.D., and Henke P.K. Mechanisms of venous thrombosis and resolution. Arterioscler Thromb Vasc Biol 28 (2008) 387-391
3. Furie B., and Furie B.C. Mechanisms of thrombus formation. N Engl J Med 359 (2008) 938-949
4. Simons K., and Ehehalt R. Cholesterol, lipid rafts, and disease. J Clin Invest 110 (2002) 597-603
5. Horstman L.L., Jy W., Jimenez J.J., Bidot C., and Ahn Y.S. New horizons in the analysis of circulating cell-derived microparticles. Keio J Med 53 (2004) 210-230
6. Berckmans R.J., Neiuwland R., Boing A.N., Romijn F.P., Hack C.E., and Sturk A. Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost 85 (2001) 639-646
7. Mackman N. On the trail of microparticles. Circ Res 104 (2009) 925-927
8. Nieuwland R., Berckmans R.J., Rotteveel-Eijkman R.C., Maquelin K.N., Roozendaal K.J., Jansen P.G., et al. Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant. Circulation 96 10 (1997) 3534-3541
9. Smalley D.M., Root K.E., Cho H., Ross M.M., and Ley K. Proteomic discovery of 21 proteins expressed in human plasma-derived but not platelet-derived microparticles. Thromb Haemost 97 (2007) 67-80
10. Abdullah N.M., Kachman M., Walker A., Hawley A.E., Wrobleski S.K., Myers D.D., et al. Microparticle surface protein are associated with experimental venous thrombosis: a preliminary study. Clin Appl Thromb Hemost 15 2 (2009) 201-208
11. Diaz J.A., and Wakefield T.W. Intrinsec and extrinsec causes of thrombosis in the superficial and deep venous system. In: Wittens C. (Ed). Innovative treatment of venous disorder (2009), Edizioni Minerva Medica, Turin 31-40
12. Frenette P.S., Denis C.V., Weiss L., Jurk K., Subbarao S., Kehrel B., et al. P-Selectin glycoprotein ligand 1 (PSGL-1) is expressed on platelets and can mediate platelet-endothelial interactions in vivo. J Exp Med 191 8 (2000) 1413-1422
13. Furie B., Furie B.C., and Flaumenhaft R. A journey with platelet P-selectin: the molecular basis of granule secretion, signalling and cell adhesion. Thromb Haemost 86 (2001) 214-221
14. Meier T.R., Myers Jr. D.D., Wrobleski S.K., Zajkowski P.J., Hawley A.E., Bedard P.W., et al. Prophylactic P-selectin inhibition with PSI-421 promotes resolution of venous thrombosis without anticoagulation. Thromb Haemost 99 2 (2008) 343-351
15. Myers Jr. D.D., Wrobleski S.K., Longo C., Bedard P.W., Kaila N., Shaw G.D., et al. Resolution of venous thrombosis using a novel oral small-molecule inhibitor of P-selectin (PSI-697) without anticoagulation. Thromb Haemost 97 3 (2007) 400-407
16. Myers Jr. D.D., Henke P.K., Bedard P.W., Wrobleski S.K., Kaila N., Shaw G., et al. Treatment with an oral small molecule inhibitor of P selectin (PSI-697) decreases vein wall injury in a rat stenosis model of venous thrombosis. J Vasc Surg 44 3 (2006) 625-632
17. Myers Jr. D.D., Rectenwald J.E., Bedard P.W., Kaila N., Shaw G.D., Schaub R.G., et al. Decreased venous thrombosis with an oral inhibitor of P selectin. J Vasc Surg 42 2 (2005) 329-336
18. Thanaporn P., Myers D.D., Wrobleski S.K., Hawley A.E., Farris D.M., Wakefield T.W., et al. P-selectin inhibition decreases post-thrombotic vein wall fibrosis in a rat model. Surgery 134 2 (2003) 365-371
19. Myers Jr. D.D., Henke P.K., Wrobleski S.K., Hawley A.E., Farris D.M., Chapman A.M., et al. P-selectin inhibition enhances thrombus resolution and decreases vein wall fibrosis in a rat model. J Vasc Surg 36 5 (2002) 928-938
20. Myers Jr. D.D., Schaub R., Wrobleski S.K., Londy III F.J., Fex B.A., Chapman A.M., et al. P-selectin antagonism causes dose-dependent venous thrombosis inhibition. Thromb Haemost 85 3 (2001) 423-429
21. Iurisci I., Cumashi A., Sherman A.A., Tsvetkov Y.E., Tinari N., Piccolo E., et al. Synthetic inhibitors of galectin-1 and -3 selectively modulate homotypic cell aggregation and tumor cell apoptosis. Anticancer Res 29 1 (2009) 403-410
22. Ramacciotti E.H.A., Wrobleski S.K., Myers Jr. D.D., Strahler J.R., Andrew P.C., Henke P.K., and Wakefield T.W. Proteomics of human microparticles after deep venous thrombosis. Journal of Thrombosis and Haemostasis 7 Supplement 2 (2009) Abstract OC-TU-060
23. Pacienza N., Pozner R.G., Bianco G.A., D'Atri L.P., Croci D.O., Negrotto S., et al. The immunoregulatory glycan-binding protein galectin-1 triggers human platelet activation. FASEB J 22 4 (2008) 1113-1123
24. Papaspyridonos M., McNeill E., de Bono J.P., Smith A., Burnand K.G., Channon K.M., et al. Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction. Arterioscler Thromb Vasc Biol 28 3 (2008) 433-440
25. Barondes S.H., Cooper D.N., Gitt M.A., and Leffler H. Galectins. Structure and function of a large family of animal lectins. J Biol Chem 269 (1994) 20807-20810
26. Thijssen V.L., Poirier F., Baum L.G., and Griffioen A.W. Galectins in the tumor endothelium: opportunities for combined cancer therapy. Blood 110 (2007) 2819-2827
27. Tinari N., Kuwabara I., Huflejt M.E., Shen P.F., Iacobelli S., and Liu F.T. Glycoprotein 90 K/MAC-2BP interacts with galectin-1 and mediates galectin-1-induced cell aggregation. Int J Cancer 91 (2001) 167-172
28. Perillo N.L., Marcus M.E., and Baum L.G. Galectins: versatile modulators of cell adhesion, cell proliferation, and cell death. J Mol Med 76 (1998) 402-412
29. Ramacciotti E., Hawley A.E., Farris D.M., Ballard N.E., Wrobleski S.K., Myers Jr. D.D., et al. Leukocyte- and platelet-derived microparticles correlate with thrombus weight and tissue factor activity in an experimental mouse model of venous thrombosis. Thromb Haemost 101 4 (2009) 748-754
30. del Conde I., Nabi F., Tonda R., Thiagarajan P., Lopez J.A., and Kleiman N.S. Effect of P-selectin on phosphatidylserine exposure and surface-dependent thrombin generation on monocytes. Arterioscler Thromb Vasc Biol 25 (2005) 1065-1070
31. Stowell S.R., Karmakar S., Stowell C.J., Dias-Baruffi M., McEver R.P., and Cummings R.D. Human galectin-1, -2, and -4 induce surface exposure of phosphatidylserine in activated human neutrophils but not in activated T cells. Blood 109 (2007) 219-227
32. Roda O., Ortiz-Zapater E., Martinez-Bosch N., Gutierrez-Gallego R., Vila-Perello M., Ampurdanes C., et al. Galectin-1 is a novel functional receptor for tissue plasminogen activator in pancreatic cancer. Gastroenterology 136 4 (2009) 1379-1390 e1-5
33. Nagaoka M.R., Strital E., Kouyoumdjian M., and Borges D.R. Participation of a galectin-dependent mechanism in the hepatic clearance of tissue-type plasminogen activator and plasma kallikrein. Thromb Res 108 (2002) 257-262
34. Wang L., Friess H., Zhu Z., Frigeri L., Zimmermann A., Korc M., et al. Galectin-1 and galectin-3 in chronic pancreatitis. Lab Invest 80 8 (2000) 1233-1241
35. Henke P.K., and Wakefield T. Thrombus resolution and vein wall injury: dependence on chemokines and leukocytes. Thromb Res 123 Suppl 4 (2009) S72-S78
36. Henderson N.C., Mackinnon A.C., Farnworth S.L., Kipari T., Haslett C., Iredale J.P., et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 172 2 (2008) 288-298
37. Henderson N.C., Mackinnon A.C., Farnworth S.L., Poirier F., Russo F.P., Iredale J.P., et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci U S A 103 13 (2006) 5060-5065
38. de Boer R.A., Voors A.A., Muntendam P., van Gilst W.H., and van Veldhuisen D.J. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail 11 (2009) 811-817
39. Cheong T.C., Shin J.Y., and Chun K.H. Silencing of galectin-3 changes the gene expression and augments the sensitivity of gastric cancer cells to chemotherapeutic agents. Can Sci (2009) Sep 14. [Epub ahead of print].
40. Lin C.I., Whang E.E., Donner D.B., Jiang X., Price D.B., Carothers A.M., et al. Galectin-3 targeted therapy with a small molecule inhibitor activates apoptosis and enhances both chemosensitivity and radiosensitivity in papillary thyroid cancer. Mol Cancer Res 7 10 (2009) 1655-1662
41. Kim S.J., Choi I.J., Cheong T.C., Lee S.J., Lotan R., Park S.H., et al. Galectin-3 Increases Gastric Cancer Cell Motility by Up-Regulating Fascin-1 Expression. Gastroenterology (2009)
42. Glinsky V.V., Kiriakova G., Glinskii O.V., Mossine V.V., Mawhinney T.P., Turk J.R., et al. Synthetic galectin-3 inhibitor increases metastatic cancer cell sensitivity to taxol-induced apoptosis in vitro and in vivo. Neoplasia 11 9 (2009) 901-909
43. Ahmed H., Cappello F., Rodolico V., and Vasta G.R. Evidence of heavy methylation in the galectin 3 promoter in early stages of prostate adenocarcinoma: development and validation of a methylated marker for early diagnosis of prostate cancer. Transl Oncol 2 (2009) 146-156
44. Iacovazzi P.A., Notarnicola M., Caruso M.G., Guerra V., Frisullo S., Altomare D.F., et al. Serum levels of galectin-3 and its ligand 90k/mac-2bp in colorectal cancer patients. Immunopharmacol Immunotoxicol (2009)
45. Vereecken P., Awada A., Suciu S., Castro G., Morandini R., Litynska A., et al. Evaluation of the prognostic significance of serum galectin-3 in American Joint Committee on Cancer stage III and stage IV melanoma patients. Melanoma Res 19 5 (2009) 316-320
46. Wang Y., Nangia-Makker P., Tait L., Balan V., Hogan V., Pienta K.J., et al. Regulation of prostate cancer progression by galectin-3. Am J Pathol 174 4 (2009) 1515-1523
47. Song S., Mazurek N., Liu C., Sun Y., Ding Q.Q., Liu K., et al. Galectin-3 mediates nuclear beta-catenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3beta activity. Cancer Res 69 4 (2009) 1343-1349
48. Yoo B.C., Hong S.H., Ku J.L., Kim Y.H., Shin Y.K., Jang S.G., et al. Galectin-3 stabilizes heterogeneous nuclear ribonucleoprotein Q to maintain proliferation of human colon cancer cells. Cell Mol Life Sci 66 2 (2009) 350-364
49. Lin C.I., Whang E.E., Abramson M.A., Donner D.B., Moore Jr. F.D., et al. Galectin-3 regulates apoptosis and doxorubicin chemoresistance in papillary thyroid cancer cells. Biochem Biophys Res Commun 379 2 (2009) 626-631
50. Eude-Le Parco I., Gendronneau G., Dang T., Delacour D., Thijssen V.L., Edelmann W., et al. Genetic assessment of the importance of galectin-3 in cancer initiation, progression, and dissemination in mice. Glycobiology 19 1 (2009) 68-75
51. Gupta S., Drazner M.H., de Lemos J.A., Thijssen V.L., and Edelmann W. Newer biomarkers in heart failure. Heart Fail Clin 5 (2009) 579-588
52. Lin Y.-H., Lin L.-Y., Wu Y.-W., Chien K.-L., Lee C.-M., Hsu R.-B., et al. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta 409 1-2 (2009) 96-99